Rick Hancock has worked in the biological contract development and manufacturing organization (CDMO) industry for over 30 years in various operational and executive roles. Rick has served as President and Chief Executive Officer of Althea Technologies, Inc., a large molecule CDMO producing a wide range of biologics, vaccines and parenteral products. In addition to Althea, Mr. Hancock has held senior management positions at The Immune Response Corporation and Hybritech Inc. (now part of Eli Lilly & Company), and is currently the Chairman of the Board and Executive Director of Argonaut Manufacturing Services, Inc., a privately-owned CDMO focused on the biotechnology and life sciences industries. In January 2022 he was appointed as Executive Chairman for BioCina, a biologics CDMO that specializes in process development and cGMP manufacture of microbial-based therapeutics and plasmid DNA, from preclinical to commercial production. Mr. Hancock received a B.A. in Microbiology from Miami University. Rick has served on the Tempo Therapeutics Board of Directors since 2016 and is an early investor in the company.